Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review

被引：71

作者：

Yeung, C. ^{[1
]}

Hilton, J. ^{[2
,3
,4
]}

Clemons, M. ^{[2
,3
,4
]}

Mazzarello, S. ^{[4
]}

Hutton, B. ^{[4
]}

Haggar, F. ^{[4
]}

Addison, C. L. ^{[4
]}

Kuchuk, I. ^{[2
,3
]}

Zhu, X. ^{[2
,3
]}

Gelmon, K. ^{[5
]}

Arnaout, A. ^{[1
,4
]}

机构：

[1] Univ Ottawa, Div Surg Oncol, Ottawa, ON, Canada

[2] Ottawa Hosp Canc Ctr, Dept Med, Div Med Oncol, Ottawa, ON, Canada

[3] Univ Ottawa, Ottawa, ON, Canada

[4] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[5] Univ British Columbia, British Columbia Canc Agcy, Div Med Oncol, Vancouver, BC, Canada

来源：

CANCER AND METASTASIS REVIEWS | 2016年 / 35卷 / 03期

关键词：

Estrogen receptor; Progesterone receptor; Her2/neu; Metastasis; Breast cancer; IN-SITU HYBRIDIZATION; COMPARATIVE GENOMIC HYBRIDIZATION; CLINICAL-PRACTICE GUIDELINE; CANCER AMERICAN SOCIETY; LYMPH-NODE METASTASES; DISTANT METASTASES; BRAIN METASTASES; BONE METASTASES; HER-2; STATUS; ENDOCRINE THERAPY;

D O I：

10.1007/s10555-016-9631-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Discordance in estrogen (ER), progesterone (PR), and HER2/neu status between primary breast tumours and metastatic disease is well recognized. In this review, we highlight how receptor discordance between primary tumours and paired metastasis can help elucidate the mechanism of metastasis but can also effect patient management and the design of future trials. Discordance rates and ranges were available from 47 studies (3384 matched primary and metastatic pairs) reporting ER, PR, and HER2/neu expression for both primary and metastatic sites. Median discordance rates for ER, PR, and HER2/neu were 14 % (range 0-67 %, IQR 9-25 %), 21 % (range 0-62 %, IQR 15-41 %), and 10 % (range 0-44 %, IQR 4-17 %), respectively. Loss of receptor expression was more common (9.17 %) than gain (4.51 %). Discordance rates varied amongst site of metastasis with ER discordance being highest in bone metastases suggesting that discordance is a true biological phenomenon. Discordance rates vary for both the biomarker and the metastatic site. Loss of expression is more common than gain. This can affect patient management as it can lead to a reduction in both the efficacy and availability of potential therapeutic agents. Future studies are recommended to explore both the mechanisms of discordance as well as its impact on patient outcome and management.

引用

页码：427 / 437

页数：11

共 95 条

[1] Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases [J].